Actively Recruiting
Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure (SANDI STUDY)
Led by Puerta de Hierro University Hospital · Updated on 2025-12-29
64
Participants Needed
1
Research Sites
147 weeks
Total Duration
On this page
Sponsors
P
Puerta de Hierro University Hospital
Lead Sponsor
H
Hospital Clinic of Barcelona
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational study is to assess the natriuretic effect of intravenous acetazolamide in patients admitted with heart failure and persistent congestion despite treatment with intravenous furosemide and sodium-glucose cotransporter type 2 (iSGLT2) inhibitors. The main question it aims to answer is whether there is a difference in natriuresis 24 hours after acetazolamide association to medical treatment recommended by the guidelines (furosemide and ISGLT2).
CONDITIONS
Official Title
Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure (SANDI STUDY)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients admitted for acute heart failure with at least one clinical sign of volume overload such as edema, ascites, or pleural effusion
- NTproBNP levels greater than 1000 pg/mL or BNP levels greater than 250 ng/mL upon admission
- Currently treated with furosemide and SGLT2 inhibitors according to European guidelines
- Indicated for additional diuretic treatment due to persistent congestion defined by ADVOR score greater than 1
You will not qualify if you...
- Systolic blood pressure less than 90 mmHg or mean arterial pressure less than 65 mmHg
- Receiving maintenance treatment with acetazolamide or treated with acetazolamide within the last month
- Expected need for intravenous inotropes, vasopressors, or nitroprusside during the study
- Contraindication to SGLT2 inhibitors
- Diagnosis of type 1 diabetes mellitus
- Glomerular filtration rate below 20 ml/min/m2 or receiving renal replacement therapy or ultrafiltration prior to the study
- Expected exposure to nephrotoxic agents such as iodinated contrast during admission
- Concurrent acute coronary syndrome
- History of congenital heart disease requiring surgical correction
- History of cardiac transplantation or use of ventricular assist device
- Pregnant or breastfeeding
- Inability to collect urine adequately
- Serum potassium less than 3.5 mEq/L
- Venous pH less than 7.30
- Severe aortic stenosis or obstructive hypertrophic cardiomyopathy
- Allergy to sulfonamides, liver cirrhosis, or kidney stones
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Julia González González
Madrid, Spain, 28222
Actively Recruiting
Research Team
J
Julia González González
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here